Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics

Vaccine. 2019 Nov 28;37(50):7394-7395. doi: 10.1016/j.vaccine.2017.09.092. Epub 2018 Feb 1.


The respiratory syncytial virus causes a considerable respiratory disease burden globally, most markedly in young infants, in low and middle income countries. A diverse product pipeline illustrates the recent intensification of research and development activities for vaccines and monoclonal antibodies against RSV. With the aim to ensure that product development activities are directed to address the public health needs, the World Health Organization has developed a research and development technical roadmap and articulated product characteristics preferences.

Keywords: Maternal immunization; Research and development; Respiratory syncytial virus; Vaccines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / biosynthesis
  • Antibodies, Viral / biosynthesis
  • Biomedical Research / organization & administration*
  • Female
  • Humans
  • Immunization / methods
  • Patient Safety
  • Pregnancy
  • Respiratory Syncytial Virus Infections / immunology
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Virus Infections / virology
  • Respiratory Syncytial Virus Vaccines / administration & dosage
  • Respiratory Syncytial Virus Vaccines / biosynthesis*
  • Respiratory Syncytial Virus, Human / immunology*
  • Respiratory Syncytial Virus, Human / pathogenicity
  • Respiratory System / immunology
  • Respiratory System / virology
  • Technology Transfer


  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Respiratory Syncytial Virus Vaccines